Pulmonary Embolism
📧 Sign up to get email alerts when something new happens for Pulmonary Embolism.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-10-03Clinical Trial Update: Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer [NA]
A completed clinical trial comparing direct oral anticoagulants (DOACs) to LMWH with or without warfarin for venous thromboembolism in cance…
-
FDA approval · 2023-09-29FDA Approved: TECHNEGAS — Original Application (Cyclomedica Australia Pty Limited)
The FDA approved Technegas as an original application for a kit to prepare Tc-99m-labeled carbon inhalation aerosol used for lung ventilatio…
-
FDA approval · 2023-08-25FDA Approved: PULMOTECH MAA — Supplemental Application (Curium US LLC)
FDA approved a supplemental application for PULMOTECH MAA, a radiopharmaceutical kit used to prepare Technetium-99m macroaggregated albumin …
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 [Phase 4]
Phase 4 trial comparing weight-adjusted versus fixed low-dose low molecular weight heparin for venous thromboembolism prevention in COVID-19…
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial [Phase 2]
Phase 2 clinical trial investigating novel α2-antiplasmin inactivation for lysis of intravascular thrombi in patients with pulmonary embolis…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-26Clinical Trial Update: Nudging Provider Adoption of Clinical Decision Support [NA]
A completed clinical trial assessing how nudging providers to adopt clinical decision support affects practice in pulmonary embolism managem…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: : Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery [Phase 4]
Phase 4 trial update evaluating the pharmacokinetics of enoxaparin following coronary artery bypass graft surgery.
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden [Phase 3]
A Phase 3 trial evaluating tPA delivered via endovascular administration for submassive pulmonary embolism to reduce thrombus burden has com…
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism [Phase 1]
Phase 1 clinical trial assessing safety and feasibility of the Bashir Endovascular Catheter for treating acute pulmonary embolism has comple…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Assessment of Acute Disease to Reduce Imaging Costs [NA]
Completed clinical trial assessing acute disease to reduce imaging costs, with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) [Phase 3]
A Phase 3 pediatric trial evaluating edoxaban for confirmed venous thromboembolism has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: An International Pulmonary Embolism Registry Using EKOS
Completed international registry study evaluating EKOS for pulmonary embolism with posted results.
-
FDA approval · 2022-11-15FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Amphastar Pharmaceuticals, Inc.)
FDA approves Amphastar Pharmaceuticals' supplemental application for enoxaparin sodium.
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism [Phase 4]
Clinical trial update for catheter-directed thrombolysis in intermediate-high risk acute pulmonary embolism (Phase 4) is currently recruitin…
-
CLINICAL_TRIALS research · 2022-11-07Clinical Trial Update: Pulmonary Embolism as a Cause of COPD Exacerbations [NA]
Clinical trial completion investigating pulmonary embolism as a contributing factor to exacerbations in chronic obstructive pulmonary diseas…
-
FDA approval · 2022-08-23FDA Approved: WARFARIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Warfarin sodium submitted by Amneal Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE) [Phase 3]
Phase 3 trial update for Air versus Oxygen in intermediate-risk pulmonary embolism completed.
-
FDA approval · 2022-07-28FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for enoxaparin sodium from Gland Pharma Limited.
-
FDA approval · 2022-06-14FDA Approved: ENOXAPARIN SODIUM — Original Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' original ANDA for enoxaparin sodium, a low molecular weight heparin, expanding availability of its …
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy [Phase 4]
Phase 4 trial comparing low-dose and intermediate-dose low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19 [Phase 3]
Phase 3 trial of enoxaparin for primary thromboprophylaxis in ambulatory COVID-19 patients was terminated.
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism [NA]
Clinical trial comparing standard catheter-directed thrombolysis with ultrasound-assisted thrombolysis for submassive pulmonary embolism has…
-
FDA approval · 2022-02-15FDA Approved: HEPARIN SODIUM — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for Heparin Sodium submitted by Sandoz Inc., indicating an additional regulatory action on this gene…
-
FDA approval · 2022-01-12FDA Approved: HEPARIN SODIUM — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for HEPARIN SODIUM from Sagent Pharmaceuticals, authorizing changes under an approved supplemental f…
-
FDA approval · 2022-01-12FDA Approved: HEPARIN SODIUM — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for Heparin Sodium from Sagent Pharmaceuticals, confirming regulatory status and updates related to …